Eranıl, IşılVardı, NigarYıldız, AzibeParlakpınar, HakanÖzhan, Onural2024-08-042024-08-0420201306-76562146-9032https://doi.org/10.5336/cardiosci.2020-74496https://search.trdizin.gov.tr/yayin/detay/447037https://hdl.handle.net/11616/90093Objevtive: The present study was designed to examine theeffects of high dose and low dose duloxetine on Cx43, a gap junction (GJ)protein; on S100A, cardiac contractility component and on certain earlycardiac impairment parameters as TnI and TnT. Material and Methods:The study was performed with 24 male Wistar Albino rats by generatingcontrol group (1 ml solvent), low-dose duloxetine (LDD) group (10mg/kg) and high-dose duloxetine (HDD) group (100 mg/kg). After theexperimental procedure, the results concerning blood pressure and heartrates of the anesthetized rats were recorded and HE staining and immunostainingof Cx43, S100A, TnI and TnT were applied to the heart tissuesections. Results: In the control group, Cx43 was stained as marked streaksbetween cardiomyocytes; TnI, TnT and S100A were stained as homogenousand dark brown in cytoplasm. Nevertheless, intensity of Cx43immunostaining showed significant increase in duloxetine- treated groups(p<0.001). TnT (p=0.024, p=0.004, p<0.05) and S100A (p<0.001) immunostainingwere low in high dose group compared to control group andlow dose group. TnI immunostaining also demonstrated significant decreasein high dose duloxetine group as compared to the control group(p<0.001). There was no statistically significant difference between groupsin terms of heart rate, ECG parameters, MDA, SOD, GSH and CATlevels (p>0.05). Conclusion: Our study reveals that duloxetine induced anincrease in the immunostaining of Cx43, and a decrease in the immunostainingof TnI, TnT and S100A, also known as early cardiac parameters.Furthermore, duloxetine was observed to show no effect on oxidant andantioxidant parameters. While heart rate remained unchanged, mean bloodpressure decreased in high dose duloxetine group. In the light of the studyoutcomes, it has been concluded that antidepressants must be administeredmore advertently in depression patients with heart disorders.eninfo:eu-repo/semantics/openAccessArticle32311612910.5336/cardiosci.2020-74496447037